Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

Medtronic's MiniMed 670G - the closest thing yet to ... system comprises a blood glucose sensor, the MiniMed 670G insulin pump and an infusion patch. Type 1 diabetes patients using the device ...

Insulin pump therapy ... A.L.P. has been a consultant for Medtronic MiniMed and has received a grant from the Medtronic/MiniMed Foundation. She has served as a consultant and/or speaker for ...

Roche is teaming up with two medical tech companies to develop an automated insulin delivery system, the first steps towards an ‘artificial pancreas.’ The Swiss pharma will work with existing ...

After receiving reports about the issue and confirming during tests, Medtronic recently issued a safety alert for users of the company's insulin pumps to monitor their glucose when flying. The ...

In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Truist raised the firm’s price target on Medtronic (MDT) to $93 from $89 and keeps a Hold rating on the shares after its Q3 earnings beat.

Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025.